Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports

S. Ferrucci, M. Romagnuolo, L. Angileri, E. Berti, S. Tavecchio

Research output: Contribution to journalArticlepeer-review

Abstract

Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients.

Original languageEnglish
Pages (from-to)e303-e304
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Volume34
Issue number7
DOIs
Publication statusPublished - 2020

Keywords

  • atopic dermatitis
  • Covid-19
  • dupilumab
  • interstitial pneumonia

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports'. Together they form a unique fingerprint.

Cite this